The increasing rate of antibiotic resistance and slowing discovery of novel antibiotic treatments presents a growing threat to public health. Here, we develop a Markov Chain model of evolution in asexually reproducing populations which is an encoding of the Strong Selection Weak Mutation model of evolution on fitness landscapes. This model associates the global properties of the fitness landscape with the algebraic properties of the Markov Chain transition matrix and allows us to derive general results on the non-commutativity and irreversibility of natural selection as well as antibiotic cycling strategies. Utilizing this formalism, we analyse 15 empirical fitness landscapes of E. coli under selection by di↵erent beta-lactam antibiotics and demonstrate that the emergence of resistance to a given antibiotic can be both hindered and promoted by di↵erent sequences of drug application. Further, we derive optimal drug application sequences with which we can probabilistically 'steer' the population through genotype space to avoid the emergence of resistance. This suggests a new strategy in the war against antibiotic-therapy-resistant organisms: drug sequencing to shepherd evolution through genotype space to states from which resistance cannot emerge and by which to maximize the chance of successful therapy.
Abstract
The increasing rate of antibiotic resistance and slowing discovery of novel antibiotic treatments presents a growing threat to public health. Here, we develop a Markov Chain model of evolution in asexually reproducing populations which is an encoding of the Strong Selection Weak Mutation model of evolution on fitness landscapes. This model associates the global properties of the fitness landscape with the algebraic properties of the Markov Chain transition matrix and allows us to derive general results on the non-commutativity and irreversibility of natural selection as well as antibiotic cycling strategies. Utilizing this formalism, we analyse 15 empirical fitness landscapes of E. coli under selection by di↵erent beta-lactam antibiotics and demonstrate that the emergence of resistance to a given antibiotic can be both hindered and promoted by di↵erent sequences of drug application. Further, we derive optimal drug application sequences with which we can probabilistically 'steer' the population through genotype space to avoid the emergence of resistance. This suggests a new strategy in the war against antibiotic-therapy-resistant organisms: drug sequencing to shepherd evolution through genotype space to states from which resistance cannot emerge and by which to maximize the chance of successful therapy.
Background: The increasing rate of antibiotic resistance and slowing discovery of novel antibiotic treatments presents a growing threat to public health. Previous studies of bacterial evolutionary dynamics have shown that populations evolving on fitness landscapes follow predictable paths. In this article, we develop a general mathematical model of evolution and hypothesise that it can be used to understand, and avoid, the emergence of antibiotic resistance.
Methods and Findings:
We develop a Markov Chain model of evolution in asexually reproducing populations which is an encoding of the Strong Selection Weak Mutation model of evolution on fitness landscapes. This model associates the global properties of the fitness landscape with the algebraic properties of the Markov Chain transition matrix and allows us to derive general results on the non-commutativity and irreversibility of natural selection as well as antibiotic cycling strategies. Utilizing this formalism, we analyse 15 empirical fitness landscapes of E. coli under selection by di↵erent -lactam antibiotics and demonstrate that the emergence of resistance to a given antibiotic can be both hindered and promoted by di↵erent sequences of drug application. We show that resistance to a given antibiotic is promoted in 61.4%, 68.6% and 70.3% of possible orderings of single, pair or triple prior drug administrations, respectively. Further, we derive optimal drug application sequences with which we can probabilistically 'steer' the population through genotype space to avoid the emergence of resistance. Conclusions: Our model provides generalisable results of interest to theorists studying evolution as well as providing specific, testable predictions for experimentalists to validate our methods.
Further, these results suggest a new strategy in the war against antibiotic-therapy-resistant organisms: drug sequencing to shepherd an evolving population through genotype space to states from which resistance cannot emerge and from which we can maximize the likelihood of successful 
for each i (see Figure 1d ). Here the parameter r 0 determines the extent to which the fitness 92 increase of a mutation a↵ects its likelihood of determining the next population genotype. In the case 93 r = 0, we have the random move SSWM model (as in Macken and Perelson [1989] , Macken et al.
94
[1991], Flyvbjerg and Lautrup [1992] ), in the limit r ! 1 we have the steepest gradient ascent 95 SSWM model (as in Kau↵man and Levin [1987] , Fontana et al. [1993] ), and for r = 1 we have 96 probability proportional to fitness increase (as in Gillespie [1983 Gillespie [ , 1984 Gillespie [ , 1991 ). This model di↵ers from the Markov model used by Sella and Hirsh [2005] to study the neutral theory of evolution as 98 we do not allow deleterious mutations to fix in the population.
99
Using this Markov Chain we can explore the possible evolutionary trajectories of a population 100 on a given fitness landscape f . We next define a collection of population row vectors µ (t) for each 101 t 2 N, where µ (t) has length 2 N and k th component which gives the probability that the population 102 has the k th genotype at time t (where the genotypes are ordered numerically according to their 103 binary value). These time steps t are an abstraction which discretely measure events of beneficial 104 mutations occurring and fixing in the population. As such, the actual time between steps t and t+1
105 is not constant but may be considered drawn from a distribution parameterized by the mutation 106 rate, reproductive rate and the number of beneficial mutations that can occur. This distribution 107 could, for example, be determined by a Moran [Moran et al., 1962] or Wright-Fisher [Wright, 1932, 108 Fisher, 1958] process depending on how we choose to interpret the fitness values given by f . If the 109 population has a genotype corresponding to a local optimum of the fitness landscape at time t then 110 there are no beneficial mutations that can occur and this definition of a time step is not well defined.
111
In this case there can be no more changes to the population under the SSWM assumptions and 112 for mathematical convenience we define the probability of a local optimum population genotype 113 remaining unchanged as one in equation 3 to ensure our model is a Markov Chain. In this case the 114 step t to t + 1 can be chosen to take some fixed arbitrary time.
115
The distribution of a population at time t is related to its initial distribution, µ (0) , by 116
Since the Markov Chain is absorbing we know that there exists some k such that P k P = P k [Grin-117 stead and Snell, 1998 ]. Consequently, we know that the matrix
exists and in fact this limit is reached after only finitely many matrix multiplications. Thus a given 119 initial population distribution µ (0) will converge to a stationary distribution µ ⇤ after a finite number 120 of steps in our model. Furthermore, if P ⇤ is known then we compute the stationary distribution
In particular, provided we assume a drug is applied for su ciently long to ensure that the disease 123 population reaches evolutionary equilibrium, we can explore the e↵ects of applying multiple drugs 124 sequentially by considering the matrices P ⇤ for the associated fitness landscapes. In the following 125 discussion we make this assumption.
126
By encoding the evolutionary dynamics in a Markov Chain we can investigate the evolutionary 127 process from an algebraic perspective. In particular, as the transition matrix P encodes all of the 128 evolutionary dynamics of the associated fitness landscape f , we can explore global properties of f 129 by considering the algebraic properties of P . In the following section we present two simple, yet 130 powerful, consequences of this observation.
131
Non-Commutativity and Cycling of Natural Selection
132
We use the Markov Chain model to formally prove that for a large class of fitness landscape pairs, 133 there is non-commutativity in the evolutionary process as described by the SSWM assumptions.
134
More precisely, consider two drugs, X and Y , with corresponding fitness landscapes x and y. We
135
wish to determine what, if any, di↵erence there is between applying X followed by Y to a population 136 as opposed to applying Y followed by X to that population. If we construct the transition matrices 137 P x and P y corresponding to x and y, respectively, and take the limits P ⇤ x and P ⇤ y , then our model 138 predicts that the ordering makes no di↵erence to the final population distribution on an initial 139 population taking genotype i if, and only if,
where µ i is row vector of length 2 N whose i th component is one and all of whose other components 141 are zero.
142
If we do not know the starting population genotype we can only guarantee that the order of 143 application is irrelevant when the outcome is the same regardless of the starting genotype. We 144 require for all possible length 2 N unit vectors
Since these unit vectors 145 form a basis of R N this occurs precisely when
Hence drug application will only commute when the corresponding limit matrices commute. In 147 practice we may be able to narrow down which genotypes are likely to constitute the population 148 through bacterial genotyping or by observing that certain strains are not viable in the wild due to 149 the high fitness cost of certain mutations. To determine how common commutativity is we first 150 tested each pair of fitness landscapes from the landscapes empirically determined by Mira et al.
[2014] for E. coli in the presence of N = 4 possible resistance conferring mutations under 15 di↵erent 152 antibiotics (listed in Table 1 ). Of these 15 antibiotics we found no commuting pairs. We then tested 153 10 6 pairs of random fitness landscapes with varying ruggedness generated according to Kau↵man's 154 NK model for generating "tunably rugged" fitness landscapes [Kau↵man and Levin, 1987, Kau↵man 155 and Weinberger, 1989] using a random neighborhood Boolean function for determining the fitness 156 contributions of each locus. We fixed N = 5 and generated each landscape by first drawing K 157 uniformly from {0, . . . , N 1} and then using Kau↵man's model to build a landscape. We found 158 that 0.132% of the landscape pairs generated had limit matrices which commuted, suggesting that 159 commutativity is rare. 160 We now turn out attention to finding antibiotic cycling strategies as in Goulart et al. [2013] .
161 Unless x is a flat landscape (taking equal values for all genotypes) there must exist a (not necessarily 162 unique) genotype j whose fitness is a minimum and which has a fitter neighbor. Such a genotype 163 satisfies P[(i ! j)] = 0 for all genotypes i. Hence if x is not flat, the limit matrix P ⇤ x has at least one 164 column of all zeros and is singular, so there cannot exist a second landscape y for which P ⇤ x P ⇤ y = I.
165
Hence there exists a unit row vector µ i for which µ i P ⇤ x P ⇤ y 6 = µ i . As the µ vectors encode probability 166 distributions this means that natural selection in our model is irreversible in the sense that for a 167 given (non-flat) landscape we cannot find another which is guaranteed to reverse its e↵ects. This 168 result precludes the existence of a general cycling strategy through which we can utilize a sequence 169 of drugs to drive evolution through a cycle in genotype space such that the disease population 170 returns to its original genotype, regardless of that starting genotype. If we do in fact know the 171 starting genotype, as we might if the disease is contracted in the wild where resistance conferring 172 mutations often carry a cost [Andersson and Hughes, 2010] making the wild-type genotype most 173 likely, then cycling strategies can be found e ciently by our model. In particular, for a given 174 starting genotype i the initial population distribution will be µ i and a sequence of drugs X 1 , . . . X k 175 with fitness landscapes x 1 , . . . x k will constitute a cycling strategy precisely when µ . When Amp is given first any of the three peaks of the landscape are accessible with most resistant genotype 1111 being most likely. If Sam is given first to steer the population to its sole peak 1111, then resistance to Amp will be guaranteed when it is applied. Alternatively, if Sam is given followed by Cpr then the population evolves to the local optima genotype 0110 of the Cpr landscape. If Amp is applied to this primed population the global optimum is inaccessible.
of the fitness landscapes for three of these antibiotics, Ampicillin (Amp), Ampicillin+Sulbactam 202 (Sam) and Cefprozil (Cpr). We will use these three fitness landscapes to demonstrate the steering 203 hypothesis explicitly. In the case of a single peaked landscape, such as that for Ampicillin + 204 Sulbactam, we cannot reduce the likelihood of resistance as all evolutionary trajectories lead to the 205 global fitness optimum. It is only when a drug has a multi-peaked landscape that we may be able 206 to avoid resistance through careful choice of preceding drugs. Of the 15 landscapes determined 207 empirically by Mira et al. [2014] only the landscape for Ampicillin+Sulbactam is single peaked. In 208 their review of empirical fitness landscapes de Visser and Krug [2014] find that biological landscapes 209 show a variable but substantial level of ruggedness suggesting that multi-peaked landscapes could be 210 quite common. Poelwijk et al. [2007, 2011] showed that reciprocal sign epistasis within a landscape 211 is necessary for the landscape to be multi-peaked.
212
In the following we take r = 0 in equation (2) and note that changing the value of r will not 213 change the accessibility of an evolutionary trajectory, hence by taking a di↵erent value of r 0 214 we will only change the result quantitatively (the probabilities may change) but not qualitatively.
215
We begin by supposing that we do not know the initial population genotype. We can model this 216 situation by taking as our prior population distribution µ = [1/2 N , . . . , 1/2 N ] which specifies that each genotype is equally likely to constitute the starting population.
If we apply the drug Amp to this population distribution we find that in the expected distribu-219 tion µ ⇤ = µP ⇤ Amp (shown in the first diamond in the top row of Figure 3 ) each of the fitness peaks 220 could be found. In particular, the most highly resistant genotype 1111 can arise in the population 221 with probability 0.62. Suppose instead we apply Sam first. In this case as the landscape is single 222 peaked the population will converge to the global optimum genotype 1111. This genotype is also 223 the global optimum of the Amp landscape and hence if we apply Amp after Sam we will encounter 224 high resistance. We have steered the population with one drug to a configuration which increases demonstrates the steering hypothesis, that evolution can be shepherded through careful orderings 230 of multiple drugs to increase or decrease the likelihood of resistance emerging.
231
To test our steering hypothesis we performed for each of the 15 drugs with landscapes derived 232 by Mira et al. [2014] an in silico test of steering using combinations of one, two or three preceding 233 drugs. Table 1 shows for each of the 15 antibiotics the combinations which reduce the probability 234 of evolution to a peak fitness genotype to the lowest possible when applied in order followed by 235 the final drug. We found that for 3 of the 15 drugs there exists another which steers an initial 236 population µ to a configuration which prevents evolution to the global fitness optimum of the 237 landscape entirely. This number rose to 6 when pairs of drugs applied sequentially are used to steer 238 the population and to 7 when triples applied in sequence were considered. 239 We then performed a second in silico experiment to find combinations of steering antibiotics 240 that maximize the probability that evolution proceeds to the least fit of the local optima of a final 241 antibiotic. Table 3 show the results of this experiment. We found that, excluding the single peaked 242 landscape for Ampicillin with Sulbactam, there exist 0 drugs for which a single other drug is able 243 to steer the population to a configuration from which evolution to only the least fit optimum is 244 possible. If pairs of drugs are used to steer there are 3 such drugs (including the example presented 245 in the above demonstration) and if triples of steering drugs are considered there remains only 3.
246
These findings suggest that through careful choice of steering drugs we may be able to prevent the 247 emergence of resistance. During these experiments we found that 14/15 of the antibiotics in our 248 experiment (Cefpodoxime (CPD) being excluded) appeared in an optimal steering combination of 249 some length.
drug orderings can also promote it. We performed an exhaustive in silico search of all singles, pairs of, and triples of steering drugs applied sequentially to prime the initial population µ for a final Table 1 : For each of the 15 antibiotics we have derived the (ordered) sets of one, two and three steering drugs which reduce the probability of evolution to the maximal fitness genotype to the lowest possible. In the case that an ordered set of steering drugs reduced the probability to 0 we have not considered ordered sets of greater length (marked as -in the table). * -as the landscape for SAM is single peaked there can be no combination of steering drugs which reduce the probability of finding the global optimum. In all experiments the initial population distribution is taken as Table 2 : For each of the 15 antibiotics we determined how many of the possible single, ordered double and ordered triple combinations of steering drugs (allowing drugs to appear multiple times in the combination and also allowing the target drug to appear as a steering drug) improved or worsened the probability of the most resistant genotype being found after the steering drugs are applied in order followed by the final target drug. In each case the initial population was given by µ = [1/2 N , . . . , 1/2 N ] and r = 0. As the SAM landscape is single peaked no combination of steering drugs will improve or worsen the outcome. As such, we have computed the overall numbers both with and without the contribution of the SAM row. due to their ine cacy.
However, a major di culty in using sequential drug treatments to steer disease populations is 285 that in order to predict the outcomes we must know the fitness landscapes of the drugs involved. De 286 Visser and Krug [2014] state that there exist less than 20 systematic studies of fitness landscapes and 287 that these studies consider between 3 and 9 possible mutations. For steering to be fully e↵ective we 288 must account for all likely fitness conferring mutations and their e↵ects on fitness under many drugs.
289
Thus, many of the studies reviewed by de Visser and Krug are insu cient for determining clinically 290 actionable steering strategies for certain diseases. Fortunately, for a number of highly resistant 291 infectious diseases [Woodford and Ellington, 2007, Jensen and Lyon, 2009] Even in the absence of actual fitness landscapes our findings should be taken as a cautionary 301 warning for multi-drug treatments, particularly those used to treat complex diseases such as mul-302 tiple infections or cancers. In the same way that the drug ordering can be used to steer away from 303 resistance we have shown it can also be used to make resistance more likely. Our results show that 304 we may be inadvertently selecting for highly resistant disease populations through arbitrary drug 305 ordering in the same way that highly resistant disease can emerge through irresponsible drug dosing.
306
This result corroborates the findings of Pena-Miller and Beardmore [2010] that antibiotic cycling 307 strategies can vary greatly in their e cacy and be both worse and better than mixing strategies.
308
If we are to avoid resistance to our most e↵ective drugs we must carefully consider how they are 309 used together, both in combination and in sequence, with other drugs and take appropriate steps 310 to reduce the risk.
311
Two major assumptions within our modeling are that drugs are administered for su ciently 312 long that evolution can converge to a local fitness optimum and that this convergence is guaranteed 313 to occur. This assumption poses two potential problems in converting our model predictions to 314 predictions of real-world bacterial evolution. The first is that if selection is strong and mutations 315 are rare then there is a possibility of the population being driven to extinction before an adaptive 316 mutation occurs. We have chosen to ignore this possibility within our modeling as in the context 317 of treating bacterial infections this would constitute a success. The second is that the time to 318 convergence could be prohibitively long for steering to constitute a realistic treatment strategy. 319 We believe that the assumption of reasonable convergence times could be valid as adaptive walks 320 in rugged landscapes are often short [Orr, 2005] . However, it has been shown that for certain 321 landscapes there can exist adaptive walks of length exponential in the number of loci [Kaznatcheev, 322 2013], but since we get to choose those drugs with which to steer we can avoid landscapes for which 323 the convergence time is prohibitively long. Further, our model is not necessarily restricted to the 324 dynamics within a single patient. Goulart et al. [2013] used fitness landscapes to explore whole 325 hospital scale antibiotic treatment strategies and our model, as an encoding of evolution on fitness 326 landscapes, is capable of making predictions at this scale also. As such, even if evolutionary 327 convergence is experimentally determined to be prohibitively slow for steering to be e↵ective as 328 a treatment for bacterial infection within a single patient, our results will still hold in scenarios 329 which admit longer timescales. Specifically, evolutionary steering could provide an e↵ective means 330 to avoid the emergence of drug resistance at the hospital scale or in life-long diseases such as HIV.
331
The Strong Selection Weak Mutation model we have used here is a highly simplified, yet well 332 studied model of evolution. The model ignores much of the complexity of the evolutionary process, 333 specifically simplifying the genotype-phenotype map, ignoring the disease microenvironment and 334 making the assumption of a monomorphic disease population in which deleterious and neutral mu- if the mutation rate is su ciently high then the population ceases to be monomorphic and forms 340 a quasispecies [Nowak, 1992 , Bull et al., 2005 . Conversely, if the population is su ciently small 341 then it becomes possible for deleterious mutations to fix [Moran et al., 1962 , Wright, 1932 , Fisher, 342 1958 ]. Finally, we have ignored the possibility of neutral spaces in the fitness landscape which have 343 been shown to have significant impact on whether non-optimal genotypes can fix in the population 344 as well as the time taken for evolution to find a locally optimal genotype [Schaper and Louis, 2014, 345 Schaper et al., 2012] . We believe that each of these breakdowns of the SSWM model will have 346 important consequences for the possibility and e cacy of steering and hence a proper treatment 347 of their implications is beyond the scope of this paper. In our future work we aim to undertake 348 a comprehensive study of the implications of population size, mutation rate, neutral drift and 349 evolutionary convergence times on the steering hypothesis.
is present in this highly simplified model it is unlikely that commutativity will emerge as more com-352 plexity is introduced. It follows that the cautionary message regarding sequential drug application 353 which results from our simplified model merits serious consideration. Whether or not measuring 354 fitness landscapes provides su cient information to correctly identify optimal drug orderings in 355 vivo is a question that cannot be answered through mathematical modeling alone. It is only by Table 3 : For each of the 15 antibiotics we have derived the (ordered) sets of one, two and three steering drugs which increase the probability of evolution to the least fit optimum genotype to the highest possible. In the case that an ordered set of steering drugs increases the probability to 1 we have not considered ordered sets of greater length (marked as -in the table). * -as the landscape for SAM is single peaked there can be no combination of steering drugs which change the probability of finding the global optimum. In all experiments the initial population distribution is taken as µ = [1/2 N , . . . , 1/2 N ] and r = 0 Bibliography
